Analyst consensus rating
Quantum Biopharma Analyst Rating: none
QNTM is rated none by 1 analysts with a $12.61 target. As of 2026-09-02.
Direct answer
Quantum Biopharma's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.61.
Forecast evidence checked September 2, 2026.
Get free Quantum Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.10
- Average price target
- $12.61
- High price target
- $12.61
- Low price target
- $12.61
- Low target gap
- +306.7%
- Target upside
- +306.7%
- High target gap
- +306.7%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Quantum Biopharma?
Quantum Biopharma has a verified none consensus. The same dataset has an average price target of $12.61.
How far are Quantum Biopharma's low and high targets from the recorded price?
The low target implies +306.7%, while the high target implies +306.7%.
How many analysts are included in Quantum Biopharma's consensus?
The verified consensus includes 1 analysts.
How is Quantum Biopharma's target upside or downside calculated?
The average target of $12.61 is divided by the recorded price of $3.10, then one is subtracted to produce +306.7%. This does not guarantee a future return.
When was Quantum Biopharma's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.